{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:58:56Z","timestamp":1772161136240,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["11A1321N"],"award-info":[{"award-number":["11A1321N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.4158\/ep-2020-0293","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T12:33:12Z","timestamp":1601037192000},"page":"44-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Added and Interpretative Value of CGM-Derived Parameters in Type 1 Diabetes Depends on the Level of Glycemic Control"],"prefix":"10.1016","volume":"27","author":[{"given":"Simon","family":"Helleputte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tine","family":"De Backer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Calders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Pauwels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samyah","family":"Shadid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Lapauw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"14","key":"10.4158\/EP-2020-0293_bib1","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.4158\/EP-2020-0293_bib2","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.2337\/dci18-0010","article-title":"Need for regulatory change to incorporate beyond A1C glycemic metrics","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"issue":"12","key":"10.4158\/EP-2020-0293_bib3","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.2337\/dc17-1624","volume":"40","author":"Agiostratidou","year":"2017","journal-title":"Diabetes Care"},{"issue":"8","key":"10.4158\/EP-2020-0293_bib4","doi-asserted-by":"crossref","first-page":"994","DOI":"10.2337\/dc17-0636","article-title":"The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading","volume":"40","author":"Beck","year":"2017","journal-title":"Diabetes Care"},{"issue":"S2","key":"10.4158\/EP-2020-0293_bib5","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1089\/dia.2017.0029","article-title":"Metrics beyond hemoglobin A1C in diabetes management: time in range, hypoglycemia, and other parameters","volume":"19","author":"Wright","year":"2017","journal-title":"Diabetes Tech Therapeut"},{"issue":"3","key":"10.4158\/EP-2020-0293_bib6","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2337\/dc18-1444","article-title":"Validation of time in range as an outcome measure for diabetes clinical trials","volume":"42","author":"Beck","year":"2019","journal-title":"Diabetes Care"},{"issue":"12","key":"10.4158\/EP-2020-0293_bib7","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2337\/dc17-1600","article-title":"International consensus on use of continuous glucose monitoring","volume":"40","author":"Danne","year":"2017","journal-title":"Diabetes Care"},{"issue":"4","key":"10.4158\/EP-2020-0293_bib8","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.diabet.2018.02.008","article-title":"The application of simple metrics in the assessment of glycemic variability","volume":"44","author":"Monnier","year":"2018","journal-title":"Diabetes Metab"},{"issue":"2","key":"10.4158\/EP-2020-0293_bib9","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00125-019-05027-0","article-title":"Positioning time in range in diabetes management","volume":"63","author":"Advani","year":"2020","journal-title":"Diabetologia"},{"issue":"2","key":"10.4158\/EP-2020-0293_bib10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2337\/cd17-0094","article-title":"Does time-in-range matter? Perspectives from people with diabetes on the success of current therapies and the drivers of improved outcomes","volume":"36","author":"Runge","year":"2018","journal-title":"Clin Diabetes"},{"issue":"8","key":"10.4158\/EP-2020-0293_bib11","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"issue":"8","key":"10.4158\/EP-2020-0293_bib12","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.2337\/dc14-2898","article-title":"Glycemic variability and diabetes complications: does it matter? Of course it does!","volume":"38","author":"Hirsch","year":"2015","journal-title":"Diabetes Care"},{"issue":"1","key":"10.4158\/EP-2020-0293_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11154-016-9325-8","article-title":"Near normal HbA1c with stable glucose homeostasis: the ultimate target\/aim of diabetes therapy","volume":"17","author":"Monnier","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"10.4158\/EP-2020-0293_bib14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4093\/dmj.2015.39.4.273","article-title":"Glycemic variability: How do we measure it and why is it important?","volume":"39","author":"Suh","year":"2015","journal-title":"Diabetes Metab J"},{"issue":"6","key":"10.4158\/EP-2020-0293_bib15","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1177\/193229680800200618","article-title":"Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it?","volume":"2","author":"Monnier","year":"2008","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"3","key":"10.4158\/EP-2020-0293_bib16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(18)30136-0","article-title":"Glycemic variability in diabetes: clinical and therapeutic implications","volume":"7","author":"Ceriello","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.4158\/EP-2020-0293_bib17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.diabres.2014.06.007","article-title":"Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes","volume":"105","author":"Smith-Palmer","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"10.4158\/EP-2020-0293_bib18","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1089\/dia.2013.0205","article-title":"Glycemic variability is higher in type 1 diabetes patients with microvascular complications irrespective of glycemic control","volume":"16","author":"Soupal","year":"2014","journal-title":"Diabetes Tech Therapeut"},{"issue":"1","key":"10.4158\/EP-2020-0293_bib19","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2337\/dc14-1801","article-title":"Glycemic variability is associated with quality of life and treatment satisfaction in patients with type 1 diabetes","volume":"38","author":"Ayano-Takahara","year":"2015","journal-title":"Diabetes Care"},{"issue":"S2","key":"10.4158\/EP-2020-0293_bib20","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1089\/dia.2019.0034","article-title":"Utilizing the ambulatory glucose profile to standardize and implement continuous glucose monitoring in clinical practice","volume":"21","author":"Johnson","year":"2019","journal-title":"Diabetes Tech Therapeut"},{"issue":"7","key":"10.4158\/EP-2020-0293_bib21","doi-asserted-by":"crossref","first-page":"832","DOI":"10.2337\/dc16-1769","article-title":"Toward defining the threshold between low and high glucose variability in diabetes","volume":"40","author":"Monnier","year":"2017","journal-title":"Diabetes Care"},{"issue":"4","key":"10.4158\/EP-2020-0293_bib22","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1177\/1932296818822496","article-title":"The relationships between time in range, hyperglycemia metrics, and HbA1c","volume":"13","author":"Beck","year":"2019","journal-title":"J\u00a0Diabetes Sci Tech"},{"issue":"5","key":"10.4158\/EP-2020-0293_bib23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1089\/dia.2017.0388","article-title":"Beyond HbA1c: comparing glycemic variability and glycemic indices in predicting hypoglycemia in type 1 and type 2 diabetes","volume":"20","author":"Rama Chandran","year":"2018","journal-title":"Diabetes Tech Therapeut"},{"issue":"10","key":"10.4158\/EP-2020-0293_bib24","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1089\/dia.2012.0062","article-title":"Hypo- and hyperglycemia in relation to the mean, standard deviation, coefficient of variation, and nature of the glucose distribution","volume":"14","author":"Rodbard","year":"2012","journal-title":"Diabetes Tech Therapeut"},{"issue":"5","key":"10.4158\/EP-2020-0293_bib25","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2337\/dc15-1990","article-title":"Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: The DCCT\/EDIC study 30-year follow-up","volume":"39","year":"2016","journal-title":"Diabetes Care"},{"issue":"1","key":"10.4158\/EP-2020-0293_bib26","first-page":"23","article-title":"Going beyond HbA1c to understand the benefits of advanced diabetes therapies","volume":"11","author":"Vigersky","year":"2019","journal-title":"J\u00a0Diabetes"},{"issue":"12","key":"10.4158\/EP-2020-0293_bib27","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1111\/dme.14065","article-title":"Associations between HbA1c and continuous glucose monitoring-derived glycemic variables","volume":"36","author":"Hirsch","year":"2019","journal-title":"Diabetic Med"},{"issue":"3","key":"10.4158\/EP-2020-0293_bib28","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s13300-019-0619-1","article-title":"A\u00a0view beyond HbA1c: role of continuous glucose monitoring","volume":"10","author":"Chehregosha","year":"2019","journal-title":"Diabetes Ther"},{"key":"10.4158\/EP-2020-0293_bib29","unstructured":"CGM and time-in-range: what do diabetes experts think about goals? https:\/\/diatribe.org\/cgm-and-time-range-what-do-diabetes-experts-think-about-goals. Accessed January 29, 2020."},{"issue":"2","key":"10.4158\/EP-2020-0293_bib30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/dia.2018.0310","article-title":"The relationship of hemoglobin A1C to time-in-range in patients with diabetes","volume":"21","author":"Vigersky","year":"2019","journal-title":"Diabetes Tech Therapeut"},{"key":"10.4158\/EP-2020-0293_bib31","doi-asserted-by":"crossref","unstructured":"Rodbard D. Glucose time in range, time above range, and time below range depend on mean or median glucose or HbA1c, glucose coefficient of variation, and shape of the glucose distribution. Diabetes Tech Therapeut. Published online ahead of print. https:\/\/doi.org\/10.1089\/dia.2019.0440","DOI":"10.1089\/dia.2019.0440"},{"issue":"3","key":"10.4158\/EP-2020-0293_bib32","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1210\/jc.2018-02409","article-title":"When HbA1c and blood glucose do not match: how much is determined by race, by genetics, by differences in mean red blood cell age?","volume":"104","author":"Cohen","year":"2019","journal-title":"J\u00a0Clin Endocrinol Met"},{"issue":"5","key":"10.4158\/EP-2020-0293_bib33","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1089\/dia.2017.0416","article-title":"Metrics to evaluate quality of glycemic control: comparison of time in target, hypoglycemic, and hyperglycemic ranges with \"risk indices\"","volume":"20","author":"Rodbard","year":"2018","journal-title":"Diabetes Tech Therapeut"},{"issue":"8","key":"10.4158\/EP-2020-0293_bib34","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1089\/dia.2019.0075","article-title":"Defining high glycemic variability in type 1 diabetes: comparison of multiple indexes to identify patients at risk of hypoglycemia","volume":"21","author":"Gomez","year":"2019","journal-title":"Diabetes Tech Therapeut"},{"issue":"12","key":"10.4158\/EP-2020-0293_bib35","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1007\/s00125-007-0820-z","article-title":"Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycemia in type 1 diabetes","volume":"50","author":"Kilpatrick","year":"2007","journal-title":"Diabetologia"},{"issue":"4","key":"10.4158\/EP-2020-0293_bib36","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2337\/dc15-2035","article-title":"Glucose variability: timing, risk analysis, and relationship to hypoglycemia in diabetes","volume":"39","author":"Kovatchev","year":"2016","journal-title":"Diabetes Care"},{"issue":"3","key":"10.4158\/EP-2020-0293_bib37","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1089\/dia.2010.0090","article-title":"Calculating the mean amplitude of glycemic excursion from continuous glucose monitoring data: an automated algorithm","volume":"13","author":"Baghurst","year":"2011","journal-title":"Diabetes Tech Therapeut"},{"issue":"S1","key":"10.4158\/EP-2020-0293_bib38","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1089\/dia.2008.0132","article-title":"Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control","volume":"11","author":"Rodbard","year":"2009","journal-title":"Diabetes Tech Therapeut"},{"issue":"2","key":"10.4158\/EP-2020-0293_bib39","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/1932296819838525","article-title":"Evaluating glucose control with a novel composite continuous glucose monitoring index","volume":"14","author":"Leelarathna","year":"2020","journal-title":"J\u00a0Diabetes Sci Tech"},{"issue":"1","key":"10.4158\/EP-2020-0293_bib40","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/1932296817718561","article-title":"The comprehensive glucose pentagon: a glucose-centric composite metric for assessing glycemic control in persons with diabetes","volume":"12","author":"Vigersky","year":"2018","journal-title":"J\u00a0Diabetes Sci Tech"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20483247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20483247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:07:07Z","timestamp":1761516427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20483247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1530891X20483247"],"URL":"https:\/\/doi.org\/10.4158\/ep-2020-0293","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Added and Interpretative Value of CGM-Derived Parameters in Type 1 Diabetes Depends on the Level of Glycemic Control","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP-2020-0293","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}